Stockreport

Sagimet Biosciences Presents Clinical Denifanstat and Preclinical FASN Inhibitor Data at AASLD - The Liver Meeting® 2024 [Yahoo! Finance]

Sagimet Biosciences Inc.  (SGMT) 
PDF Both artificial intelligence (AI) and conventional pathology demonstrated denifanstat's strong anti-fibrotic activity FASN inhibitor treatment reduced atherosclerosis [Read more]